The Dedham Group is the premier US oncology & specialty therapeutics strategy consulting firm that combines deep clinical expertise in specialty disease areas, commercial & market access expertise and proprietary analytics to provide highly differentiated recommendations & strategic support to our clients in the pharmaceutical and biotech industry. Our work focuses on being highly data-driven and developing highly custom and integrated strategies in exciting areas of clinical innovation which span oncology, cell & gene therapy, immunology, neurology, rare diseases and precision medicine. We are deeply embedded with our clients which span senior leaders across sales & marketing, market access, distribution & patient services, pricing & contracting and channel strategy across marquee brands on the cutting edge of clinical innovation from many of the most admired companies. Our team is comprised of highly talented entrepreneurial, collaborative and creative leaders that are focused on insights development, storytelling and creating custom strategies & products for our strategic clients, maintaining the high quality & deep specialization expectations of a boutique firm. Our organization prides itself on being a merit-driven, team-based, high-performance culture where our people care greatly about their clients’ careers, the impact of their work and the overall well-being of their colleagues.

After pursuing a multitude of entrepreneurial endeavors and leading other health care strategy consultancies, our founders sought to create something more than just an oncology and specialty therapeutics market access firm, a top tier strategy house, a customer-centric market research company, a meticulous data analytics shop, an innovative software tools group, or a C-suite management consultancy.

We aspired for something more impactful, sustainable, and rewarding for every individual in our organization as well as for each client with whom we partner.

We set out to develop a health care innovation organization that could separate the background “noise” from what warrants investment in our highly complex, rapidly evolving marketplace lacking transparency to enable our pharmaceutical and biotech clients to make better decisions and flourish.

Today, ten years later, we are the preeminent U.S. market access oncology and specialty strategy partner, grounded in the structure and logic of the strategy consulting discipline, bolstered by our robust data set continuously enriched via our unequaled specialty access panel of the most highly influential access and value influencers in the U.S.

With a unique staffing model of highly structured and collaborative creative thinkers akin to an oncology and specialty think tank, we have increasingly come to be viewed as an influencer in our industry. At the interface of clinical, economic, and operational evolving needs, the Dedham Group has become the go-to resource for addressing the challenges faced by the world’s leading life sciences organizations.

Now, The Dedham Group is proud to be a part of Norstella, an organization that consists of market-leading pharmaceutical solutions providers united under one goal: to improve patient access to life-saving therapies. Within this organization, The Dedham Group plays a key role helping commercial teams navigate the oncology space to get much-needed drugs to market—and helping clients connect the dots from pipeline to patient.